Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects
NCT02660736
Completed
Albiglutide (Alb) is a novel analogue of glucagon-like peptide-1 (GLP-1) has been developed and approved for the treatment of type 2 diabetes mellitus. Currently, lyophilized albiglutide and the diluent are provided in a dual chamber Cartridge (DCC) single-dose pen injector, requiring reconstitution prior to use. A liquid formulation of albiglutide will enable the use of a liquid product in a ready-to-use single dose auto-injector. To support the development of the liquid auto-injector product,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/08/2016
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
NCT00518115
Completed
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/03/2016
Locations: GSK Investigational Site, Anniston, Alabama +162 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
NCT01607450
Completed
The objective of this proposal is to provide quantitative dose-response data for effects of GLP-1 on myocardial glucose uptake in healthy control subjects and obese type 2 diabetic subjects, in support of the design of later studies evaluating therapeutic applications of GLP-1 to heart disease. Aim 1: To measure the effects of GLP-1 infusion on myocardial fuel selection in lean healthy humans under fasting (fatty acid-dominant) conditions. Four groups of 10 lean healthy subjects will be studied... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/19/2016
Locations: Indiana Clinical Research Center, Indianapolis, Indiana
Conditions: Type 2 Diabetes Mellitus, Healthy
Register for Updates
The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man
NCT02518932
Unknown
To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/07/2015
Locations: ICON PLC, San Antonio, Texas
Conditions: Insulin Resistance
Register for Updates
Dose-response Study of Exendin-9,39 on Glucose Metabolism
NCT01218633
Completed
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a d... Read More
Gender:
ALL
Ages:
Between 20 years and 45 years
Trial Updated:
01/18/2013
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Register for Updates
GLP1R Polymorphisms and Response to GLP1
NCT00588380
Completed
Glucagon-like Peptide-1 (GLP-1) is an important incretin hormone which acts as a powerful insulin secretagogue. Defects in GLP-1 synthesis and secretion are thought to be part of the pathogenesis of type 2 diabetes. Furthermore GLP-1 based therapy is an important part of the therapeutic armamentarium for the treatment of type 2 diabetes. The GLP-1 receptor (GLP1R) is the principal site of action of GLP-1 and GLP-1 receptor agonists like exenatide and liraglutide. The gene coding for this recepto... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
12/14/2011
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Diabetes
Register for Updates